These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
552 related articles for article (PubMed ID: 27216271)
1. Antimicrobial Susceptibility among European Gram-Negative and Gram-Positive Isolates Collected as Part of the Tigecycline Evaluation and Surveillance Trial (2004-2014). Rodloff AC; Dowzicky MJ Chemotherapy; 2017; 62(1):1-11. PubMed ID: 27216271 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial. Vega S; Dowzicky MJ Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Balode A; Punda-Polić V; Dowzicky MJ Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898 [TBL] [Abstract][Full Text] [Related]
4. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Dowzicky MJ; Park CH Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial. Zhang Z; Chen M; Yu Y; Pan S; Liu Y Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. Kanj SS; Whitelaw A; Dowzicky MJ Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313 [TBL] [Abstract][Full Text] [Related]
8. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016. Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099 [TBL] [Abstract][Full Text] [Related]
9. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016. Dowzicky MJ; Chmelařová E J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209 [TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Bertrand X; Dowzicky MJ Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196 [TBL] [Abstract][Full Text] [Related]
12. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010. Liu JW; Ko WC; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Chen YH; Lu PL; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR Antimicrob Agents Chemother; 2012 Mar; 56(3):1414-7. PubMed ID: 22155819 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial. Morfin-Otero R; Noriega ER; Dowzicky MJ Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014. Tärnberg M; Nilsson LE; Dowzicky MJ Int J Infect Dis; 2016 Aug; 49():141-8. PubMed ID: 27343986 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009). Andrasevic AT; Dowzicky MJ Int J Antimicrob Agents; 2012 Feb; 39(2):115-23. PubMed ID: 22189391 [TBL] [Abstract][Full Text] [Related]
16. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010. Fernández-Canigia L; Dowzicky MJ Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014. Marco F; Dowzicky MJ J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007. Garrison MW; Mutters R; Dowzicky MJ Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity among gram-positive and gram-negative organisms collected from the Asia-Pacific region as part of the Tigecycline Evaluation and Surveillance Trial: Comparison of 2015 results with previous years. Yang Q; Xu YC; Kiratisin P; Dowzicky MJ Diagn Microbiol Infect Dis; 2017 Dec; 89(4):314-323. PubMed ID: 28951056 [TBL] [Abstract][Full Text] [Related]
20. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007). Seifert H; Dowzicky MJ Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]